• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Researchers find long-term statin use linked to lower POAG risk



A study suggests that patients who used statins for five years or more had a 21% lower chance of primary open-angle glaucoma

A team of researchers have conducted a study bringing the connection between statin use and the risk of primary open-angle glaucoma (POAG) into sharper focus. Investigators from Brigham and Women’s Hospital have found that using statins for five or more years is linked to a lower risk for POAG.

Jae Hee Kang, ScD, assistant professor of medicine in the Channing Division of Network Medicine at Brigham and Women’s Hospital, was lead author of the study.

In vitro studies conducted in the 2000s indicated that statins may have the ability to decrease IOP and provide protection for the retinal ganglion cells against damage from glaucoma, according to the authors of a newly published study by Kang, et al.1 Related: Current trends, challenges in glaucoma 

“Our study suggests possible protective associations beyond cardiovascular conditions for longterm statin use,” Dr. Kang pointed out. “Statins may also strengthen neuroprotective mechanisms that prevent degeneration of cells in the optic nerve.”

The association between statin use and POAG had been investigated previously, but the results were inconclusive and contradictory. Only relatively short courses of statin use were investigated.

“Our primary a priori hypothesis was that longer duration of statin use is associated with a lower risk of POAG, and our secondary hypothesis was that higher cholesterol levels are associated with a higher risk of POAG,” Dr. Kang and her team reported.

Dr. Kang and her team tracked 136,782 healthy patients (113,702 women, 23,080 men) who were 40 years of age and older who did not have glaucoma. The patients were drawn from the Nurses’ Health Study (NHS) (patients followed from 2000 to 2014, Nurses’ Health Study 2 (NHS2) (patients followed from 1999-2015), and the Health Professionals Follow-up Study (HPFS) (patients followed from 2000 to 2014).

A review of the medical records confirmed the incident cases of POAG. The study data regarding development of glaucoma, assessment of high cholesterol, total serum cholesterol, statin use, and use of other cholesterol-lowering drugs had been collected biennially from the patients. The main outcomes measures were the multivariable adjusted relative risks (RR) and the 95% confidence intervals (CIs).

Related: Glaucoma, retinal diseases present collaborative opportunities Study findings
A total of 886 confirmed cases of incident POAG were identified (522 women in the NHS, 208 men in the HPFS, and 156 women in the NHS2; mean patient age, 68.5 years) during 1,485,498 personyears of follow-up, the authors reported.

“Individuals who used statins for five or more years were more likely to have reported a history of elevated cholesterol levels, higher total serum cholesterol levels, and a higher prevalence of cardiovascular disease and risk factors,” the investigators said.

Dr. Kang’s team noted that longer statin use was not associated with known risk factors for glaucoma such as African American race/ethnicity or having a family history of glaucoma.

Importantly, they found that every 20 mg/dL increase in the total serum cholesterol value was associated with a 7% increase in the risk of development of POAG (RR, 1.07; CI, 1.02-1.11).

Related: Study: Statins associated with lower risk of developing POAG

This finding reached significance (p = 0.004). They also reported that any self-reported history of elevated cholesterol levels was associated with a higher risk of development of POAG (RR, 1.17; CI, 1.00-1.37), and that a history of any use of statins was associated with a lower risk of development of POAG (RR, 0.85 CI; 0.73-0.99).

An important finding involved the longer use of statin, i.e., patients who used statins for five or more years had a 21% lower risk of development of POAG compared with patients who had never used statins (RR, 0.79; CI, 0.65-0.97).

Age factor 
“The inverse association between use of statins for five years or longer and risk of POAG was stronger among those who were 65 years or older (RR, 0.70; CI, 0.56-0.87) than among those younger than 65 years (RR, 1.05, CI, 0.68-1.63),” the investigators said.

Effects of stains
This class of drugs may lower the risk of development of POAG by IOP-lowering and neuroprotective mechanisms.

“Statins affect the activities of myosin II adenosine triphosphatase and p kinase in the trabecular network that increase nitric oxide production and aqueous outflow facility, which may lead to some IOP lowering,” the investigators explained.

Related: Looking beyond IOP when managing glaucoma patients 

“Greater production of nitric oxide also would increase the blood flow to the optic nerve.”

Additional neuroprotective effects that protect the retinal ganglion cells include anti-excitotoxic, anti-apoptotic, and anti-inflammatory effects.

“Among adults aged 40 years and older, higher serum cholesterol levels were associated with higher risk of POAG,” the investigators concluded. “Five or more years of statin use compared with no use of statins was associated with a lower risk of POAG.” 

Read more by Lynda Charters 





1. Jae H. Kang, Tahani Boumenna, Joshua D. Stein, Anthony Khawaja, Bernard A. Rosner, Janey L. Wiggs, Louis R. Pasquale. Association of statin use and high serum cholesterol levels with risk of primary open-angle glaucoma. JAMA Ophthalmology, 2019.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Deb Ristvedt, DO's CIME 2024 Talk Highlights Innovations in Treating Glaucoma via the Trabecular Meshwork
Dr. Inder Paul Singh's Insights: Improving Glaucoma Outcomes with Early Intervention and Reduced Medication
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
© 2024 MJH Life Sciences

All rights reserved.